194 related articles for article (PubMed ID: 37195515)
1. Digital Tools-Regulatory Considerations for Application in Clinical Trials.
Gelis L; Stoeckert I; Podhaisky HP
Ther Innov Regul Sci; 2023 Jul; 57(4):769-782. PubMed ID: 37195515
[TBL] [Abstract][Full Text] [Related]
2. Innovation Process and Industrial System of US Food and Drug Administration-Approved Software as a Medical Device: Review and Content Analysis.
Yu J; Zhang J; Sengoku S
J Med Internet Res; 2023 Nov; 25():e47505. PubMed ID: 37999948
[TBL] [Abstract][Full Text] [Related]
3. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations.
Ghadanian M; Schafheutle E
Ther Innov Regul Sci; 2024 Jan; 58(1):79-113. PubMed ID: 37861859
[TBL] [Abstract][Full Text] [Related]
4. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
5. The current status of breakthrough devices designation in the United States and innovative medical devices designation in Korea for digital health software.
Woo JH; Kim EC; Kim SM
Expert Rev Med Devices; 2022 Mar; 19(3):213-228. PubMed ID: 35255755
[TBL] [Abstract][Full Text] [Related]
6. Data Integrity: History, Issues, and Remediation of Issues.
Rattan AK
PDA J Pharm Sci Technol; 2018; 72(2):105-116. PubMed ID: 29158286
[TBL] [Abstract][Full Text] [Related]
7. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.
Barry E; Walsh JA; Weinrich SL; Beaupre D; Blasi E; Arenson DR; Jacobs IA
Paediatr Drugs; 2021 Jul; 23(4):381-394. PubMed ID: 34173206
[TBL] [Abstract][Full Text] [Related]
8. Guidelines, editors, pharma and the biological paradigm shift.
Singh AR; Singh SA
Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
[TBL] [Abstract][Full Text] [Related]
9. Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.
Romero K; Clay R; Hanna D
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S5-9. PubMed ID: 26224771
[TBL] [Abstract][Full Text] [Related]
10. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
11. Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health.
Ronquillo JG; Zuckerman DM
Milbank Q; 2017 Sep; 95(3):535-553. PubMed ID: 28895231
[TBL] [Abstract][Full Text] [Related]
12. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
13. Clinical Simulation in the Regulation of Software as a Medical Device: An eDelphi Study.
O'Driscoll F; O'Brien N; Guo C; Prime M; Darzi A; Ghafur S
JMIR Form Res; 2024 Jun; 8():e56241. PubMed ID: 38917454
[TBL] [Abstract][Full Text] [Related]
14. Provable Data Integrity in the Pharmaceutical Industry Based on Version Control Systems and the Blockchain.
Steinwandter V; Herwig C
PDA J Pharm Sci Technol; 2019; 73(4):373-390. PubMed ID: 30770485
[TBL] [Abstract][Full Text] [Related]
15. Legal regulation of the production and trade of medical devices and medical equipment in the EU and US: experience for Ukraine.
Pashkov V; Kotvitska A; Harkusha A
Wiad Lek; 2017; 70(3 pt 2):614-618. PubMed ID: 28713093
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Latin America Regulation Landscape and International Reference Health Authorities to Hasten Drug Registration and Clinical Research Applications.
Argotti U; Leyens L; Lisbona C; López P; Alonso-Orgaz S; Nevado A; Cozzi V
Ther Innov Regul Sci; 2023 Nov; 57(6):1287-1297. PubMed ID: 37682461
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers as drug development tools: discovery, validation, qualification and use.
Kraus VB
Nat Rev Rheumatol; 2018 Jun; 14(6):354-362. PubMed ID: 29760435
[TBL] [Abstract][Full Text] [Related]
18. Development and Regulation of Connected Combined Products: Reflections From the Medtech & Pharma Platform Association.
Kühler TC; Schoenmakers M; Shergold O; Affolter S; Bolislis WR; Foster R; Gardner P; Hruschka S; Jomini T; Kaveripakam S; Mayerhofer K; Scherini T; Swierczynska M; Vandal G; Fürst-Ladani S
Clin Ther; 2022 May; 44(5):768-782. PubMed ID: 35393132
[TBL] [Abstract][Full Text] [Related]
19. Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.
Xie J; Li J; Liu Y; Wang H; Wang Y; Yang Y; Chen Y; Jiang R; Shao R
BMJ Open; 2023 Jun; 13(6):e069132. PubMed ID: 37286329
[TBL] [Abstract][Full Text] [Related]
20. Developing a Digital Solution for Remote Assessment in Multiple Sclerosis: From Concept to Software as a Medical Device.
van der Walt A; Butzkueven H; Shin RK; Midaglia L; Capezzuto L; Lindemann M; Davies G; Butler LM; Costantino C; Montalban X
Brain Sci; 2021 Sep; 11(9):. PubMed ID: 34573267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
